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Background: Nontuberculous mycobacteria (NTM) are emerging infections in the CF population.
Aims: To assess NTM infection prevalence and associated features in our CF clinic population.
Methods: Patient records, 2002–2011, were reviewed for NTM infection. FEV1, pancreatic function, sputum microbiology, and serum cytokines
were compared in patients with and without NTM infection.
Results: Incidence rate of NTM infection increased from 0 in 2002 to 8.7% in 2011 (p b 0.001). NTM infection prevalence increased 3-fold from
5% (4/79) in 2003 to 14.5% (16/110) in 2011 (p = 0.05). Prevalence of chronic NTM lung disease has decreased somewhat since a peak in 2009,
with institution of aggressive triple therapy. Of NTM-infected compared to uninfected patients, 88.2% vs. 60.3% had a known ‘severe’ CFTR
genotype (p = 0.04), 88.2% vs. 58.9% were pancreatic insufﬁcient (p = 0.02); 70.6% vs. 43.8% had chronic Pseudomonas aeruginosa (p = 0.06);
75% vs. 32% had Aspergillus infection (p = 0.007) and 23.5% vs 2.7% had allergic bronchopulmonary aspergillosis (p = 0.01). Patients infected
with Mycobacterium abscessus had increased TGF-β, TNF-α, IL-1β, IL-2, IL-4 and IL-5 levels (p b 0.05). There was no difference in cytokine
levels for all NTM infected compared to uninfected patients. M. abscessus comprised 46% of all NTM infections. Comparing M. abscessus versus
other NTM, duration was 10.5 (1–118) months versus 1 (1–70) month, median (range) (p = 0.004); lung disease occurred in 69% versus 17%
(p = 0.0004), with sputum conversion in 4/11 versus 5/6, respectively (NS).
Conclusions: NTM incidence and prevalence have increased dramatically in our CF clinic, associated with a severe CF genotype and phenotype.
M. abscessus, the most prevalent NTM, caused prolonged infection despite therapy. There has been some decrease in the prevalence of NTM lung
disease since 2009.
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As survival in cystic fibrosis (CF) increases, the emergence of
new and resistant bacterial infections, including nontuberculous
mycobacteria (NTM) is an increasing concern [1]. NTM infection
was first described in CF patients in the 1980s [2,3] but was
considered rare and of unknown pathogenicity. In the 1990s an⁎ Corresponding author at: Graub CFCenter and Pulmonary Institute, Schneider
Children's Medical Center of Israel, 14 Kaplan Street, Petah, Tikva 49202, Israel.
E-mail address: hblau@post.tau.ac.il (H. Blau).
http://dx.doi.org/10.1016/j.jcf.2014.05.008
1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Aincreasing number of CF centers reported NTM infection, with
various single-site studies describing about 1300 CF patients, and
an estimated NTM prevalence of 2–28% [4]. In 2002, a
cross-sectional multi-center study of CF patients in the United
States, reported an overall NTM prevalence of 13% [4], but no
data was given regarding changing prevalence over time.
Indeed, the prevalence of NTM as a cause of significant
pulmonary disease has been increasing globally [5]. Although
variable, prevalence within the CF population is also rising and
could be associated with increasing survival as well as prolonged
antibiotic therapy [6–8]. In addition, the infection may bell rights reserved.
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clinicians and microbiologists of the consequences of NTM lung
disease. A previous study of NTM in Israeli CF patients showed
that the prevalence was highest (up to 29%) in the center and
south of the country and in the coastal cities where the weather is
hot and humid, rather than the dry mountains of Jerusalem [9].
Species diversification of NTM within the CF population
appears to vary with geographical distribution. In the United
States, Mycobacterium avium complex (MAC), followed by
Mycobacterium kansasii and Mycobacterium abscessus are the
most frequently recognized pulmonary pathogens [4]. In Europe,
however,M. abscessus appears to be the major pathogen in CF [6].
NTM are ubiquitous and are readily recovered from
environmental sources, such as soil, water, plants and animals.
Tap-water is considered the major reservoir for most NTM
species pathogenic to humans, and bacteria can be isolated
from the solid–liquid interface biofilm, especially within piping
systems [10]. This renders the mycobacteria less susceptible to
disinfectants and antimicrobial therapy.
Although in the past NTM was not considered a major
pathogen, descriptions of fulminant NTM infections, particularly
withM. abscessus, are increasingly evident in the CF population
[5,11,12]. Other NTM species are of undetermined and variable
clinical importance [13]. Nosocomial spread of NTM infection in
CF was previously considered unlikely [4]. Recently however,
whole-genome sequencing revealed frequent transmission of
multidrug resistant M. abscessus, subspecies massiliense [14].
This may have been by indirect means, and occurred despite
conventional cross-infection measures.
Normal host defenses against NTM include a well-orchestrated
inflammatory response. Initially, mycobacteria bind Toll-like-
Receptor (TLR)2 on macrophages which produce TNF-α and
IL-12, up-regulating a TH1 response and IFN-gamma production,
activating NK-cells and resulting in intra-cellular mycobacteria
killing. Multiple cytokines are involved, including GM-CSF,
IL1β, IL2 and IL8. Deficiency of leptin as in malnutrition
increases susceptibility to rapidly growing mycobacteria, as does
increased IL10. Similarly, immune dysregulation, with increased
TH2 or decreased TH1 response, may enhance NTM infection
[15–17].
We have had the impression that NTM lung disease has been
increasing steadily in our CF clinic. As a result, aggressive,
prolonged triple therapy has been instituted in recent years. We
therefore decided to review and analyze the incidence and
prevalence of NTM infection and lung disease in the past
decade, and to correlate this with demographic, clinical and
immunologic patient data.2. Methods
This was an observational, longitudinal, retrospective study
conducted at a single CF center in Israel. The study was
approved by the ethics committee of SCMCI, approval no.
7043 0295-12.
The study population included CF patients attending the
Graub CF Center at Schneider Children's Medical Center ofIsrael (SCMCI) from 2002 till 2011, and diagnosed with CF
according to accepted criteria [18].
As part of the routine protocol, sputum was cultured for
nontuberculous mycobacteria (NTM) as well as other bacteria
and fungi, every 3–6 months. In patients previously diagnosed
with NTM infection, sputum was sent for NTM culture at every
clinic visit (every 1–2 months). In addition, sputum culture for
NTM was performed when clinical deterioration in pulmonary
disease was not clearly explained by the presence of other
bacteria or fungi.
3. NTM laboratory diagnostic protocol
Expectorated sputum was transferred immediately and
analyzed at the mycobacteria laboratory within the Department
of Microbiology, Rabin Medical Center, adjacent to SCMCI.
Specimens underwent mucolysis using AlphaTec NAC-PAC-
Red (N-Acetyl-Cysteine) and then decontamination using 3%
NaOH for 15 min followed by addition of buffer (AlphaTec
NPC67, Vancouver, Washington, USA) to neutralize the NaOH.
Several drops of the resultant fluid were used for Ziehl–Neelsen
(ZN) staining, and the rest was inoculated onto Loewenstein–
Jensen (LJ) slanted agar (Loewenstein–Jensen + Glycerol +
PACT, Heipha, Germany) and BD BACTEC MGIT incubator
tubes. LJ tubes were placed in a 37 °C incubator and inspected
weekly for growth till 8 weeks. MGIT tubes were placed in
computerized incubators at 37 °C. Once growth was seen in
either media, a repeat ZN stain was performed and further
identification was performed by biochemical PCR using
Mycobacteria Genotype kits (Hain Life Science, Germany).
Susceptibility testing was performed at the Mycobacterium
Reference Laboratory, the Public Health Laboratory of the
Ministry of Health, Abu-Kabir, Israel.
Both the clinical and the laboratory diagnostic protocol were
consistent and did not change throughout the study period.
4. Patient data collection
CF patient charts were reviewed and data recorded from
January 2002 to December 2011. Microbiologic data included
results of NTM culture, ZN staining, species of NTM and
results of culture for other bacteria and fungi.
Annual incidence rate and prevalence were assessed
throughout this period as was the use of azithromycin.
In 2008 a cross-sectional assay for cytokines was performed
for all CF patients aged N2 years at the Graub center, while in a
stable pulmonary state. We now reviewed levels of cytokines
considered to have a role in host defense against NTM (IL1β,
IL2, IL-4, IL-5, IL-10, IL-12, IL-17, TNF-α, INF-γ, GM-CSF
and leptin). Demographic, genetic and clinical data for all clinic
patients are presented at the time of cytokine testing in 2008,
including gender, age, height, weight, CFTR mutations, sweat
chloride, FEV1 (best value measured during that year),
pancreatic enzyme therapy, azithromycin therapy (number of
years with at least 3 months of therapy), presence of CF related
diabetes treated with insulin, and 25-OH vitamin D levels and
were compared between patients with at least one positive
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NTM during this period. Genotype and cytokines measured in
2008 were also compared for patients with or without
M. abscessus infection during these years.5. Definitions
5.1. NTM lung disease versus presence of NTM infection
We defined patients as having ‘NTM lung disease’ if they
had clinical symptoms as well as radiological signs and
microbiologic criteria as by the ATS consensus statement (at
least 2 positive NTM cultures from separate expectorated
sputum samples) [19]. In addition, we required that repeat
cultures grew the same mycobacteria species, with 12 months
or less between two positive NTM cultures. Patients were
defined as having a presence of NTM infection if they had only
one positive NTM sputum culture during the observation
period, and no unexplained clinical deterioration. The overlap
between clinical signs of CF and NTM lung disease made ‘the
absence of clinical symptoms’ impossible to include in defining
the presence of NTM infection in this group [19]. We chose the
term ‘presence of infection’ rather than ‘colonization’ for this
group, as airway and lung parenchyma pathologic involvement
have been demonstrated even in this situation [20].5.2. Sputum conversion
Patients were considered to have NTM sputum conversion
if cultures were negative for one year after being diagnosed
with NTM lung disease [21]. Spontaneous conversion implies
conversion without receiving specific anti-mycobacterial
therapy.5.3. NTM incidence and prevalence
Annual NTM incidence from 2002 till 2011 refers to the
total number of patients with the presence of a NTM positive
sputum culture for the first time during each year. Annual
incidence rate refers to patients with a new NTM positive
sputum culture as a percentage of all clinic patients at the end of
that year (“new” culture includes patients already infected with
one strain of NTM who acquired a different strain).
Annual NTM prevalence refers to the percentage of clinic
patients at the end of each year with at least 1 positive NTM
culture during that year. Annual NTM lung disease prevalence
refers to the percentage of clinic patients at the end of each year
with at least 2 positive NTM cultures during that year.5.4. Chronic Pseudomonas aeruginosa infection
At least 2 sputum cultures in a year, of which N50% were
positive for P. aeruginosa [22].5.5. Years of azithromycin therapy
This refers to the number of years with N3 months of
continuous therapy in that year, between 2006 and 2009,
compared for NTM positive and negative patients in 2008.5.6. CFTR genotype severity
We classified patients as having a severe CFTR genotype if
they had 2 mutations from class I or class II, known to be
associated with minimal CFTR function and a mild CFTR
genotype if they had at least one mutation from class IV or V,
known to be associated with residual CFTR function [23]. If
patients had 1 unknown and 1 severe mutation or 2 unknown
mutations we classified them as of unknown genotype severity
and did not include them in the analysis of the effect of
genotype on NTM infection. Our cohort did not include any
patients with class III mutations.5.7. Statistical analysis
We summarized patient demographic, genetic and clinical
characteristics using median and range or mean and standard
deviation as appropriate. We calculated proportions for categor-
ical variables. These parameters were compared between
NTM-positive and NTM-negative subjects by unpaired non-
parametric (Wilcoxon) tests, or χ2 test, as appropriate. Duration
of NTM positivity for different NTM species was compared
using unpaired non-parametric (Wilcoxon) test, while the
prevalence of NTM infection versus lung disease for different
NTM species was compared using χ2 test. Fisher's exact test was
used to compare CFTR allele frequency and genotype severity in
M. abscessus positive and NTM positive patients compared to
uninfected patients. The coefficient of determination (R2) for the
time dependent linear trend of the incidence and prevalence of
NTM-positive patients was calculated. All analyses were 2-tailed,
and a p-value b0.05 was considered significant. Statistical
analyses were performed using SPSS software (v. 21, IBM®
SPSS® Inc., Chicago, IL).6. Results
6.1. Incidence and prevalence of NTM infection
The annual incidence rate of NTM infection increased
between 2002 and 2011 from 0 to 9%, R2 = 0.8776, p b 0.001
(Fig. 1). This was despite a constant rate of 4–5 NTM cultures/
patient/year over the decade reviewed (E-Table 1, online data
supplement).
Prevalence of patients with NTM positive cultures was 5%
(4/79 patients) in 2003 but subsequently increased almost
3-fold, to 14.5% (16/110) by 2011, R2 = 0.9103, p = 0.05
(Fig. 2). The prevalence of NTM lung disease appears to have
peaked in 2009 and be decreasing somewhat since then (Fig. 2).
Fig. 1. Increasing incidence rate (% newly infected patients of total clinic patients each year) of new NTM infection over time, at the Graub CF center, SCMCI, from
2002 until 2011.
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The total number of CF patients at the Graub CF center,
SCMCI, increased from 70 in 2002 to 110 in 2011. Demographic
and clinical characteristics of NTM-positive versus NTM-negativeFig. 2. Increasing NTM prevalence over time at the Graub CF center, SCMCI is depic
2011.patients for 2008, the year when cytokine studies were done, are
summarized in Table 1. At this time there were 90 CF patients,
54% males, age 16.9 (0–59) years, median (range).
All 90 patients in the 2008 cohort were genotyped: 50 had 2
class I or II mutations (‘severe’ genotype), 25 had at least 1 classted from 2003, once uniform management of NTM in clinic was instituted, until
Table 2
CFTR mutation severity for NTM positive and negative patients.
CFTR
mutation
severity
All
subjects
M.
abscessus
positive
M.
abscessus
negative
NTM
positive ⁎
NTM
negative ⁎
n 90 9 81 17 73
Severe, n (%) 50
(55.6%)
8 (88.9%) 42 (51.9%) 15
(88.2%)
35
(47.9%)
Mild, n (%) 25
(27.8%)
1 (11.1%) 24 (29.6%) 2 (11.8%) 23
(31.5%)
Unknown, n (%) 15
(16.7%)
0 (0%) 15 (18.5%) 0 (0%) 15
(20.5%)
CFTR mutation severity was classified as ‘severe’, with minimal residual
function, if patients had 2 mutations belonging to class I or II, ‘mild’, with
residual CFTR function, if patients had at least one mutation from class IV or V
and unknown if both mutations were unknown or 1 was class I or II and 1
unknown.
⁎ p = 0.04 comparing NTM positive and NTM negative subjects and p = 0.25
comparing M. abscessus positive and negative subjects for mutation severity;
subjects with unknown mutation severity were excluded from the analysis.
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genotype severity (Table 2). The most frequent CFTR mutations
in our cohort were W1282X, ΔF508, G542X, D1152H,
3849 + 10kbC→T. No CFTR allele was more prevalent in
patients with M. abscessus or who were NTM positive (E-Table
2, on-line data supplement). When considering the 75 patients
with known CFTR genotype severity, 15/17 (88.2%) NTM
positive patients had a severe genotype, compared with 35/58
(60.3%) NTM negative (p = 0.04). Of the nine patients with M.
abscessus infection 8 (88.9%) had a severe genotype compared to
42/66 (66.7%) patients without M. abscessus (p = 0.26).
Patients with presence of NTM infection were more likely to
be pancreatic insufficient compared to those without NTM
infection (p = 0.02) and had more P. aeruginosa chronic
infection (p = 0.06). Despite this, BMI-SDS, and FEV1 were
similar in both groups. There was no correlation with duration of
azithromycin therapy or number of days of intravenous antibiotic
therapy. A strong correlation was found between the presence
of NTM infection and airway infection with Aspergillus (p =
0.003), as well as with the presence of allergic bronchopulmonary
aspergillosis (ABPA) (p = 0.01).
6.3. NTM species distribution
Relative frequency of infection with the various NTM
species is shown in Fig. 3. Rapidly growing mycobacteria
(RGM) included M. abscessus, Mycobacterium chelonae and
Mycobacterium fortuitum. Slow growing mycobacteria (SGM)
included M. avium, Mycobacterium simiae and Mycobacterium
intracellulare. RGM, and in particular the M. abscessusTable 1
CF patient demographic and clinical characteristics. a
NTM positive b NTM negative b p-Value
Patients, n (% total) 17 (18.9%) 73 (81.1%)
Age (years), median (range) 17.8 (4.3–55.3) 15.2 (0.2–59.3) 0.42
Male, n (%) 11 (64.7%) 38 (52.1%) 0.42
Sweat chloride (mmol/L),
median (range)
101.0 (59.0–145.0) 91.0 (10.0–150.0) 0.46
BMI-SDS, mean ± SD −0.02 ± 0.55 0.2 ± 0.76 0.18
CF related diabetes, n (%) 4 (23.5%) 7 (9.6%) 0.21
Pancreatic insufficiency,
n (%)
15 (88.2%) 43 (58.9%) 0.02
FEV1 (%predicted),
median (range)
94.1 (40.0–125.0) 92.9 (32.0–120.0) 0.92
25-OH vitamin D (ng/ml),
median (range)
24.1 (15.7–41.8) 22.8 (7.1–45.6) 0.21
Pseudomonas aeruginosa,
n (%)
12 (70.6%) 32 (43.8%) 0.06
Aspergillus, n (%) 12 (70.6%) 18 (24.6%) 0.003
ABPA, n (%) 4 (23.5%) 2 (2.7%) 0.01
IV antibiotics days,
median (range)
0 (0–161) 0 (0–84) 0.25
Azithromycin c years,
median (range)
0 (0–4) 2 (0–4) 0.14
ABPA = allergic bronchopulmonary aspergillosis.
a In 2008.
b ≥1 sputum culture positive for NTM from 2006 to 2009.
c In 2006–2009.complex, make up the majority of cases throughout the decade.
M. abscessus comprised an average of 46% of all mycobacteria
isolates annually. M. avium and M. intracellulare, together
comprising the M. avium complex, were isolated in approxi-
mately 24% of cases. In 2002 only M. abscessus and M. avium
were identified, but institution of PCR species identification
permitted more precise identification of NTM species in
subsequent years. Mycobacterium mucogenicum, Mycobacteri-
um interjectum, Mycobacterium peregrinum, Mycobacterium
smegmatis andM. kansasii, each appeared only once during the
entire observation period and are not shown in Fig. 3.
6.4. Duration of NTM infection and lung disease
M. abscessus was most frequently associated with NTM
lung disease, whereas other NTM species were more likely to
be associated with transient infection (Table 3) (p = 0.0004).
Duration of infection for M. abscessus compared to all other
NTM species was 10.5 (1–118) months compared to 1 (1–70)
month, respectively, median (range) (p = 0.004).
As the timeline in Fig. 4 demonstrates, of the 16 patients
with sputum cultures positive for M. abscessus, many had lung
disease persisting for months or years (Fig. 4A), in contrast to
non-abscessus NTM where transient infection was most
common (Fig. 4B) (p = 0.004). This must be qualified, with
regard to new NTM infection in 2011, where the duration is as
yet unknown.
Of 11 patients who developed M. abscessus lung disease
(Fig. 5A), 2 converted spontaneously after only 2 positive
cultures, and 9 had sputum cultures persistently positive for
several years. One was observed without treatment as there was
no apparent clinical impact, but eight received triple therapy
(oral and/or IV), according to susceptibility results for months
to years continuously. Only two converted to negative sputum.
In one patient, persistent M. abscessus led to respiratory failure
and lung transplantation, with subsequent sputum conversion
(total 5 years of continuous IV triple therapy). In contrast, for
Fig. 3. Relative frequency of mycobacteria species during the observation period: Four representative years are demonstrated: A. 2002; B. 2005; C. 2008; D. 2011; M.av =
Mycobacterium avium, M.abs = Mycobacterium abscessus, M.int = Mycobacterium intracellulare, M.sim = Mycobacterium simiae, M.fort = Mycobacterium fortuitum,
M.chel = Mycobacterium chelonae.
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conversion occurred spontaneously in 2 and following triple
therapy in 3. Only 1 patient had persistent disease despite
prolonged therapy. Thus, 4/11 (36%) with M. abscessusTable 3
NTM infection versus lung disease, by NTM species, 2002–2011.
NTM species Duration
(months)
NTM
infection
NTM lung
disease
Median
(range)
n (%) n (%)
M. abscessus 10.5 (1–118) ⁎ 5 (31%) 11 (69%) ⁎⁎
All other NTM (non-abscessus) 1 (1–70) ⁎ 30 (83%) 6 (17%) ⁎⁎
NTM species M. intracellulare/
avium
1 (1–70) 10 3
M. simiae 5 (1–22) 4 2
M. chelonae 1 (1–1) 3 0
M. fortuitum 1 (1–17) 9 1
M. kansasii 1 (1–1) 1 0
M. gordonae 1 (1–1) 2 0
M. mucogenicum 1 (1–1) 1 0
⁎ p = 0.004, comparing duration of M. abscessus infection to infection by all
other NTM.
⁎⁎ p = 0.0004, infection versus lung disease for M. abscessus compared to all
other NTM.compared to 5/6 (83%) with other NTM lung disease achieved
sputum conversion (which did not reach significance, possibly
due to small numbers) (p = 0.13).
6.5. Serum cytokines in NTM positive compared to NTM
negative patients
There was a wide range in values for all serum cytokines
measured in 2008. TGF-β, TNF-α, IL-1β, IL-2, IL-4 and IL-5
levels were increased significantly in the 9 patients positive for
M. abscessus compared to M. abscessus negative patients and
significance was maintained when looking only at the 6 patients
with M. abscessus lung disease (Table 4). No association was
found with NTM infection or lung disease between 2006 and
2009, for IL-4, IL-5, IL-10, IL-12, IL-17, TGF-β, TNF-α or
INF-γ and leptin. GMCSF levels tended to be lower in patients
with NTM infection compared to those without, 8.4 (2.7–35.3)
pg/ml versus 15.4 (0.5–57.9) pg/ml, median (range), respec-
tively (p = 0.06), E-Table 3, on-line data supplement.
7. Discussion
Over the past decade we have found that the incidence and
prevalence of NTM infections within our CF clinic population
Fig. 4. Timeline representing duration of nontuberculous mycobacteria (NTM) infection or lung disease. 4A. M. abscessus, and 4B. Mycobacteria other than
M. abscessus. Each horizontal level represents a single patient. Interrupted thick lines represent discrete episodes of infection, at least 12 months apart, not necessarily
with the same NTM species. Shortest lines represent a single positive culture.
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abscessus infection. Many have persistent NTM lung disease
and sputum conversion often fails, despite prolonged multi-
drug intravenous antibiotic therapy. This can be associated with
inexorable clinical deterioration over many years and in one
case led to the need for lung transplantation. This is in contrast
with infection by other NTM species which is often transient
and may not require treatment. Although new cases with apresence of NTM infection are increasing, NTM lung disease
peaked in our population in 2009 and has decreased since then.
Possibly this is due to isolation of patients with NTM lung
disease to prevent cross infection, as well as aggressive triple
therapy where indicated clinically. Previous reports from
different CF centers around the world describe a wide range
of NTM prevalence, from 3.3% to 24%, probably depending on
geographic region [4,6]. NTM prevalence reported by US and
A) Management and outcome of 
   M. abscessus lung disease 
B) Management and outcome of 
non-abscessus NTM lung disease 
Fig. 5. Management of patients and outcome of nontuberculous mycobacteria
(NTM) lung disease. 5A. 11 patients with M. abscessus lung disease, and 5B. 6
patients with lung disease associated with mycobacteria other than M.
abscessus.
Table 4
Serum cytokines in M. abscessus positive and negative patients.
M. abscessus positive
n = 9
M. abscessus negative
n = 81
Median Range Median Range p-Value
GM-CSF 16.2 2.7–35.5 12.4 0.5–57.9 0.99
TGF-β 2273 1214–3731 1314 0.1–5348 0.02 ⁎
INF-γ 5 1.2–30.2 2.8 0.8–55.9 0.30
TNF-α 1.6 0.3–17.8 0.3 0.3–17.3 0.01 ⁎
IL-1β 6.8 0.7–30.7 2.3 0.4–97.4 0.02 ⁎
IL-2 1.9 1.0–6.6 1.0 1.0–10.4 0.04 ⁎
IL-4 2 0.4–8.8 0.7 0.1–10.3 0.03 ⁎
IL-5 62.7 12.4–232.1 22.1 0.2–203.5 0.01 ⁎
IL-6 31.4 1.0–97.6 7.0 0.4–805.4 0.08
IL-8 4.4 1.0–13.2 2.2 0.5–762.8 0.11
IL-10 0.5 0.3–4.6 0.3 0.3–4.1 0.25
IL-12 p40 10.9 1.0–22.5 13.2 0.4–69.7 0.53
IL-12 p70 12.7 4.8–77.5 6.6 0.6–101.4 0.08
IL-17A 0.8 0.5–6.0 0.5 0.5–11.6 0.50
IL-17F 25.5 2.7–34.1 14.0 0.0–156.9 0.27
IL-22 134.8 0.4–455.6 53.5 0.4–532.8 0.36
Serum cytokine levels taken in 2008 and compared for patients with Npositive
sputum culture forM. abscessus compared to patients negative forM. abscessus
between 2006 and 2009.
⁎ p-Value of b0.05 which is considered signiﬁcant.
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under-reporting and lack of definitions for many aspects of
NTM infection and disease. Fortunately, international guide-
lines for CF-related NTM disease are now in preparation.
NTM were previously considered commensal organisms,
ubiquitous in the environment, e.g. soil and water, and nosocomial
transmission was not thought to occur [4,12] However, a recent
publication [14] demonstrated a high rate of transmission of M.
abscessus between CF patients despite stringent segregation, and
suggested that transmission occurred indirectly, through fomite
contamination or aerosols during physiotherapy and spirometry
testing. The study also demonstrated that a low inoculum is
sufficient for infection from smear-negative, infected patients.
This has provoked great concern regarding the need for extreme
preventative measures. We did not perform whole genome
sequencing of the mycobacteria isolated from our clinic patients,
and therefore do not know whether cross-infection within our
clinic explains some of the rising NTM incidence. We now
segregate NTM-infected CF patients and are aiming forsingle-use rooms and whole genome sequencing for our entire
patient cohort.
In our clinic, NTM infection was associated with a ‘severe’
CFTR genotype and pancreatic insufficiency and thus, classic
CF. This differs from the findings of Olivier [4] who described
NTM as mainly affecting milder and older patients. However,
as MAC was the main infecting organism in the USA study, the
profile of disease was likely to be different [26].
We found a strong association between ABPA and NTM
infection which we previously described in a smaller cohort of
our patients [11] and which has been shown by others [27]. We
suspect a specific immune dysregulation is involved in this
subgroup, as compared to the rest of the CF population possibly
associated with an increased TH2 response and this might
increase susceptibility to NTM infection.
As cytokines were only measured at a single time point, it is
difficult to say which predisposed to the M. abscessus infection
and which reflect an inflammatory response following infection.
Interestingly we found that patients with M. abscessus infection
had significantly increased levels of IL-4, IL-5, associated with a
TH2 response, as well as increased levels of pro-inflammatory
cytokines including TNF-α and IL-1β. In a study of immune
response toM. abscessus infection in a murine model, analysis of
lung homogenates showed that both Th1 and Th2 cytokines
increased simultaneously following high dose infection [28]. As
an intracellular pathogen, M. abscessus elicits an innate immune
response and production of pro-inflammatory cytokines, includ-
ing TNF-α and IL-1β via TLR2 and MAPK pathways. Indeed,
TNF-α production has been shown to be increased further
following M. abscessus infection than following M. avium
infection [29]. When comparing all NTM positive to NTM
negative patients in our study, cytokine differences were not
found, possibly reflecting the fact that lung disease was
61O. Bar-On et al. / Journal of Cystic Fibrosis 14 (2015) 53–62associated mainly with M. abscessus infection whereas transient
infection was more common for other NTM species.
There was also an association between NTM infection and
aspergillus infection, even in patients without ABPA. Possibly
both these infections were a marker for a more severe CF
phenotype or certain features of the host-lung morphology or
long-term cumulative antibiotic therapy, although these fea-
tures were not assessed in this study.
As in this study, M. abscessus was the most prevalent
species in reports from the UK and Greece [30] but in contrast
to reports from other CF centers internationally [26]. In
particular, MAC is the predominant mycobacteria isolated
from the respiratory tract of patients in North America,
although M. abscessus has been rising and now represents
20% of NTM. This may be explained by regional variation of
the distribution of mycobacteria within the environment. It
could also explain the differences in pathogenicity described
for NTM in CF worldwide.
This study has several limitations. Firstly, as a retrospective
single center study, it cannot accurately determine the
importance of various associations observed within the patient
cohort or what the true risk factors are for the rise in NTM
incidence observed. In view of the major pathogenetic
potential, in particular for M. abscessus, we support the need
for a multi-center multinational prospective study of NTM
infection in CF. A second limitation is that we measured
cytokine levels at a single time point, not necessarily of most
significance in relation to onset of NTM infection, and
variability was great within our CF cohort. Furthermore,
serum cytokine levels may not reflect the local milieu within
the lung, and future BAL or induced sputum studies may shed
further light on this question.
In conclusion, we describe a persistent increase in the
incidence of NTM infection over the past decade, with a peak
in NTM lung disease in 2009 and some decrease since then in
our CF population. This was associated with pancreatic
insufficiency, chronic P. aeruginosa, aspergillus and ABPA.
In particular, M. abscessus sputum conversion often failed,
even with prolonged triple therapy, and NTM lung disease
could be associated with inexorable pulmonary decline. The
possible role of transmission between patients is of concern.
Take home message
NTM infection, with prolonged M. abscessus lung disease,
increased dramatically, over the past decade at our CF
center.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.05.008.
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